Over the last two decades, a number of large outbreaks of acute respiratory illnesses, such as the 2009 influenza A (H1N1) virus and the 2019 novel coronavirus epidemic, have emerged and posed a significant danger to the worldwide population’s health. The coronavirus epidemic brings to mind pandemics that have instilled enormous dread in our minds, such as SARS, Zika virus (ZIKV), Middle East respiratory syndrome (MERS), and H1N1 flu. The two major epidemics, 2019-nCoV and H1N1, have had a significant impact on people. As a result, in this investigation, researchers examined certain clinical, demographic, and laboratory results to establish the differences between H1N1 influenza and coronavirus disease-2019 (COVID-19) in order to provide suitable pharmacological treatment methods. In terms of laboratory results, both 2019-nCoV and H1N1 patients had leukopenia as the primary finding. Given that comparable diagnostic techniques are utilized for H1N1 and 2019-nCoV patients, as well as the same clinical and laboratory characteristics, it is fair to assume that lopinavir/ritonavir and nucleoside analogs might be pharmacological therapy choices for 2019-nCoV patients.
However, given the current emergency situation, the primary and fundamental intervention technique is infection management in order to prevent the spread of COVID-19. It is advised, however, that public health experts keep a careful eye on the situation because the more knowledge we have about this new virus and the impending pandemic, the sooner we can respond.